Agilent Technologies Inc. (A)
Seeking Clues to Agilent (A) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Agilent (A) for the quarter ended April 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
What Makes Agilent (A) a New Buy Stock
Agilent (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Boston Trust Walden Corp Sells 21,880 Shares of Agilent Technologies, Inc. $A
Boston Trust Walden Corp trimmed its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 9.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 207,881 shares of the medical research company's stock after selling 21,880 shares during the quarter. Boston
Why Is Agilent (A) Down 6.2% Since Last Earnings Report?
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript
Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript
Aquatic Capital Management LLC Decreases Stake in Agilent Technologies, Inc. $A
Aquatic Capital Management LLC reduced its position in Agilent Technologies, Inc. (NYSE: A) by 43.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 53,601 shares of the medical research company's stock after selling 41,359 shares during the period. Aquatic Capital Management LLC's holdings in
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies ( NYSE:A ) while trimming its price target on Icon PLC ( NASDAQ:ICLR ) following a turbulent earnings season for the sector.
Agilent to acquire Biocare Medical in $950 million all-cash deal
Life sciences firm Agilent Technologies said on Monday that it will acquire clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million.
Investing in Agilent (A)? Don't Miss Assessing Its International Revenue Trends
Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Agilent Q1 Earnings Miss Estimates, Revenues Up Y/Y, Shares Fall
A posts Q1 revenue growth and beats sales estimates, but margin pressure and earnings miss send shares lower in pre-market trade.
Agilent Technologies, Inc. (A) Q1 2026 Earnings Call Transcript
Agilent Technologies, Inc. (A) Q1 2026 Earnings Call Transcript
Agilent (A) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended January 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
